CRP and myocardial infarction: In the recently released randomized controlled trials (RCTs) of anti-inflammatory treatment, the COLCOT and CANTOS trials [8, 9] showed that the patients with myocardial infarction with high baseline CRP levels reduced the risk of MACEs through anti-inflammatory treatment, but the baseline CRP of patients with myocardial infarction included in the CIRT trial [35] was only 1.6 mg/L, and the results showed that anti-inflammatory treatment did not improve the prognosis of patients.